Premium
Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease
Author(s) -
Golde Todd E.,
Eriksen Jason L.,
Weggen Sascha,
Sagi Sarah A.,
Koo Edward H.
Publication year - 2002
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.10093
Subject(s) - nonsteroidal , disease , drug , inflammation , medicine , drug development , mechanism of action , pharmacology , mechanism (biology) , alzheimer's disease , immunology , chemistry , biochemistry , philosophy , epistemology , in vitro
One feature of the end‐stage pathology of Alzheimer's disease (AD) is the presence of numerous inflammatory markers associated with the amyloid β protein (Aβ) deposits in the brain. Experimental data strongly suggests that Aβ aggregates can incite an inflammatory response, but there are also data suggesting that inflammation can promote Aβ production and deposition. Thus, antiinflammatory drugs may have some role in AD therapy. This idea is supported by epidemiologic data, which shows that long‐term use of nonsteroidal antiinflammatory drugs (NSAIDs) confers protection from the development of AD. Significantly, oral salicylates have not been consistently shown to confer protection. Such studies have raised questions regarding the target or targets of NSAIDs that account for their apparent protection from AD. We have recently found that some NSAIDs have a novel mechanism of action, namely, selective lowering of the pathogenic Aβ42 peptide, that could contribute to their efficacy in AD. Further study will be needed to determine if the classic antiinflammatory properties of NSAIDs, the Aβ42‐lowering property, another known or unknown property, or a combination of these contributes to NSAIDs apparent ability to protect individuals from the development of AD. Drug Dev. Res. 56:415–420, 2002. © Wiley‐Liss, Inc.